echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The disease control rate exceeds 95%!

    The disease control rate exceeds 95%!

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    SourceGuanlan Pharmaceutical

    On March 29, Yingli Pharmaceuticals announced that its PI3Kδ inhibitor linperlisib (YY-20394) for the treatment of relapsed/refractory follicular lymphoma phase 2 registration clinical trial was initially completed.

    Linperlisib is an oral PI3Kδ inhibitor developed by Yingli Pharmaceutical.

    This announcement is a single-arm, open, multi-center phase 2 clinical trial (YY-20394-002), which aims to evaluate the effectiveness and safety of linperlisib in the treatment of patients with relapsed and/or refractory follicular lymphoma.

    Phase 2 registration clinical data showed that linperlisib showed significant clinical benefit in subjects with relapsed/refractory follicular lymphoma: Among 89 evaluable patients with relapsed/refractory follicular lymphoma, linperlisib reached An objective remission rate of more than 80%, and a disease control rate of more than 95%.

    In addition, from the analysis of statistical results, oral administration of linperlisib is safe, controllable and well tolerated.

    Yingli Pharmaceutical plans to communicate with multiple regulatory authorities around the world on the results of the Phase 2 clinical trial of linperlisib for the treatment of relapsed/refractory follicular lymphoma, and will gradually announce the data.

    ▲Linperlisib molecular structure (picture source: reference [1])

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.